Both miR-148a and miR-152 were shown to directly bind to 3UTR of IGF-1R and inhibit IGF-1R-mediated PI3K/AKT activation
doi: 10.1016/S0272-6386(12)80667-6 292
meanwhile, systemic inflammatory response may lead to systemic coagulation activation and microvascular failure, further aggravating organ dysfunction [16]
What about India
What clinicians consider when advising against GLP-1 use during breastfeeding Lack of large, controlled lactation safety trials Unknown effects on infant growth or neurodevelopment Uncertainty about effects on milk supply or composition Elective nature of GLP-1 therapy for weight loss Availability of safer alternatives after breastfeeding ends Why FDA and medical guidance remains cautious FDA and specialty guidance emphasize caution during breastfeeding for several consistent reasons: Insufficient data: FDA labeling states there are inadequate data on GLP-1 medication effects in breastfed infants.,, Milk supply unknowns: It is not known whether GLP-1 medications affect milk supply (volume) or milk composition., Infant vulnerability: Early infancy is a sensitive developmental period, increasing caution when medication effects are unknown. Elective vs essential use: For weight management, potential maternal benefit often does not outweigh theoretical infant risk.,, Do semaglutide and tirzepatide pass into breast milk
Unfortunately, most adult diets do not include enough of the micronutrients we need for optimal wellness
